Strengthening its over the counter (OTC) portfolio, via this product, Dr. Reddy’s has further expanded its offerings in the therapeutic area of pain relief to consumers, the company said in a statement.
In India, the market for pain relief products is approximately Rs 1,700 crore. Pain relief sprays are growing 20 times faster than creams and gels, indicating a trend of changing consumer preferences.
The formulation for Nise D Spray comprises three key ingredients which get absorbed quicker, penetrate deep to reach the source of pain and reduce inflammation. Nise, as a brand has been providing effective relief to consumers by killing pain over the years.
“Nise D Spray marks our entry into the new segment and further boosts our OTC portfolio. Nise gel has made a remarkable headway into the market and looking at the market dynamics and consumer requirements, we expect Nise D Spray to have a great momentum and significant market share across regions,” said Dr Reddy’s executive vice president and head, branded markets (India & Emerging countries) M V Ramana.